JERUSALEM, Jan 29 (Reuters) - Teva Pharmaceutical

Industries reported a slightly larger than expected

rise in fourth-quarter profit, helped by double-digit sales

gains in a trio of its branded drugs to treat migraines,

Huntington's disease and schizophrenia.

The world's largest generic drugmaker said on

Wednesday it earned 71 cents per diluted share excluding

one-time items in the October-December quarter, down from $1.00

per share a year earlier. Revenue fell 5% to $4.2 billion.

Analysts had forecast earnings of 70 cents per share

ex-items for the Israel-based company on revenue of $4.13

billion, LSEG I/B/E/S data showed.